| Literature DB >> 21731372 |
R D Lele1.
Abstract
This paper reviews the pharmacology of Indian medicinal plants, starting with the historical background of European work on the subject beginning as early as the 17th century, and tracing its history through the work of Sen and Bose in the 1930's, and Vakhil's historic 1949 paper on Sarpaghanda. The often crucial role of patient feedback in early discoveries is highlighted, as is the time lag between proof of pharmacological action and identification of the active principle, and subsequent elucidation of mechanism of action. In the case of Indian plants in the 20th century this process sometimes took almost 50 years. Reserpine and its mechanisms are given in detail, and its current relevance to public health discussed. The foundation of present day methods of pharmacology is briefly presented so the complexity of methods used to identify properties of Ayurveda derived drugs like forskolin and baicalein, and their bioavailability, may be better appreciated. Ayurveda derived anti-oxidants and their levels of action, immuno-modulators, particularly with respect to the NF-kB pathway and its implications for cancer control, are all considered. The example of curcumin derived from turmeric is explained in more detail, because of its role in cancer prevention. Finally, the paper emphasizes the importance of Ayurveda's concepts of rasayana as a form of dietary chemo-prevention; the significance of ahar, diet, in Ayurveda's aspiration to prevent disease and restore health thus becomes clear. Understood in this light, Ayurveda may transcend pharmacology as a treatment paradigm.Entities:
Keywords: Ayurveda; Reverse Pharmacology
Year: 2010 PMID: 21731372 PMCID: PMC3117317 DOI: 10.4103/0975-9476.74435
Source DB: PubMed Journal: J Ayurveda Integr Med ISSN: 0975-9476
Plant origin of drugs used in modern medicine
| Drug | Plant source | Clinical observation | Molecular mechanism of action |
|---|---|---|---|
| Artemether | Qinshausu | Chloroquin resistant malaria | Heme–mediated decomposition of endoperoxide, generating free radicals |
| Atropin | Antispasmodic | MAch receptors | |
| Caffeine | Stimulant | Adenosine receptors | |
| Indian Hemp | Sedation, antiemetic | Cannabinoid receptors | |
| Cocaine | Leaves of Coca | Addictive drug | CB1 CB2 |
| Colchicine | Relief of pain in gout | Blocks DAT, NET, SERT Inhibits release of leukocyte-derived chemotactic factors | |
| Digitalis | Foxglove | Relief of dropsy | Na+K+ATPase |
| Emetine | Ipecacuana | Amoebic dysentery | Inhibits protein synthesis in eukaryotic cells |
| Ephedrine | Ephedra | Bronchodilator | α, β adrenoreceptor agonist |
| Eserine | Calabar beans | Pupil constriction | Reversible cholinesterase inhibitor |
| Morphine | Analgesic | Opioid receptors | |
| Nicotine | Tobacco plant | Stimulant | Nicotinic Ach receptors |
| Quinine | Cinchona bark | Fever due to malaria | Inhibits hemozoin crystallization – aggregation of cytotoxic heme |
| Reserpine | Sarpagandha | Sedation, lowers BP | Blocks VMAT1, VMAT2 |
| Salicylic acid | Fever and pain relief | Cox inhibitor NFKB inhibitor | |
| Strychnine | Hyperexcitability convulsions | Blocks glycine receptors | |
| Vincristine | Anticancer | Binds to tubulin disrupts microtubule assembly |
List of receptors and transporters for which specific radiolabeled ligands are available for drug screening
| Non peptide | Peptide |
|---|---|
| Acetyl choline receptors | Angiotensin |
| Muscarinic M1, M2, M3, M4, M5 | AT1 AT2 |
| Nicotinic four types | Bombesin |
| Adenosine | BB1 BB2, BB3 |
| A1, A2,A, A2B, A3 | Bradykinin |
| Adrenoceptors | B1, B2 |
| α1A, α2B, α1∆, α2A, α2B, α2X;, | Calcitonin-gene related peptide |
| α2∆ | receptor |
| β1, β2, β3 | CGRP1, 2, amylin, adrenomedullin |
| Biogenic amine transporters | Chemokine |
| NET, DAT, SERT | CXCR1, 2, 3, 4 |
| Cannabinoid | CCR4, 5, 6, 7, 8, 9, 10, 11 |
| CB1, CB2 | XCRI, CX3CRI, DARC |
| Dopamine | ECRF3, US28, KSHV |
| D1, D2, D3, D4, D5 | Cholecystokinin/gastrin |
| GABA receptors | CCKA, CCKB |
| A, B, C | Corticotropin releasing factor |
| GABA transporters | CRF1, CRF2α, 2β, 2γ, CRF-BP |
| GAT-11, 2, 3, BGT, VGAT | Cytokine |
| Excitatory amoinoacid transporters | Hematoprotein family |
| EAAT1, T2, T3, T4, T5 | Il-2, 3, 4, 5, 6, 7, 8, 9, 10, 11, |
| Glutamate | 12, 12, 15, 16, 17, 19, 21, 22 |
| G protein family: eight types | Tumor necrosis family 9 |
| Ion channel family: three types | ILIR/TIR |
| Glycinic receptor | IL1R1, IL1RII, IL-18 |
| GlyT1, GlyT2 | TNF receptor family |
| Histamine | TNFRSF 1, 2, 3, 4, 5, 6, 7, 8, 9, |
| H1, H2, H3, H4 | 10A, B, C, D, 11 |
| Imidazoline binding sites | Endothelin |
| I1, I2, I3 | ETA ETB |
| Leukotriene | Galanin |
| BLT1, BLT2, CysLT, CysLT2 | R1 R2 R3 |
| Lysophospholipid | Melanocortin |
| P1, P2, P3, P4, P5 | MCR1, 2, 3, 4, 5, 6 |
| Melanin concentrating hormone | Neuropeptidase |
| MCH1, MCH2 | Neuropeptide |
| Melatonin | Y1 Y2 Y4 Y5 Y6 |
| MT1, MT2, MT3 | Neurotensin |
| Platelet activating factor receptor | NT1 NT2 |
| Prostanoid | Neurotrophin |
| EP1, EP2, EP3, EP4 | TrK A, B, C, p75 |
| P2 P2X subtype (ion channel | Opiod receptors |
| family) 7 | |
| P2Y subtype (G protein family) 7 | δ (OP1) k(OP2) μ(OP3), OP4 |
| Serotonin | Orexin receptors |
| 5HT1A 5HT1B, 5HT1D SHT1f | O×1 O×2 |
| 5HT2, 5HT1D 5HT2c 5HT3 5HT4 | Proteinase-activated |
| 5HT5 5HT 5HT6 5HT7 | PAR1, 2, 3 |
| Ion channels: | Somatostatin |
| Calcium channels | SST 1, 2, 3, 4,5 |
| Chloride channels | Tachykinin |
| Potassium channels | NK1, NK2, NK3 |
| Sodium channels | VIP |
| Sigma receptor | VPAC11, 2, PAC1 |
| Vanilloid receptors | Vasopressin and oxytocin |
| receptor | |
| V1a, V1b, V2, OT | VEGF |
| 1, 2, 3 | |
| Intracellular signaling enzymes/receptors | |
| Adenylyl cyclases – 10 isoenzymes | |
| Ca+ calmodulin dependent protein kinases | |
| Caspases | |
| Cyclic nucleotide-regulated kinases | |
| Cyclic nucleotide phosphodiesterases | |
| Cyclin-dependent kinases | |
| G-protein coupled receptor kinases | |
| Heteromeric G proteins | |
| Ins P3/Ryanodine receptors | |
| Intracellular receptors (non-steroid) (steroid) | |
| Mitogen-activated protein kinase | |
| Nitric oxide synthases | |
| PDK1-PKB/AKT signaling | |
| Peroxisome proliferators activated receptor (PPARs) | |
| Phosphoinositide kinases | |
| Phospholipase A2 | |
| Phospholipase C (phosphoinositide specific) | |
| Phospholipase D (phosphatidylcholine specific) | |
| Phosphoprotein phosphatases | |
| Serine/threonine phosphatases | |
| Protein tyrosine phosphatases | |
| Protein kinase C | |
| Protein prenyl transferases | |
| Small molecular weight G proteins | |
| Tyrosine kinases | |
| Receptor linked | |
| Non-receptor linked | |
| Ion channel | |
| Calcium: L, T, N, P, Q, R | |
| Chloride: CIC, CFTR, GABA/glycine | |
| Potassium: KIR, ATP-sensitive, Tandem pore, voltage-gated Ca2+ | |
| activated, KCNQ, HERG | |
| Sodium: I, II, IIA, III, μ1, PN1, V1, h1, PN3βNS, SNS2 | |
| Vanilloid receptors (capsicum – capsaicin) activated |
Figure 1Ayurvedic anti-oxidants
Figure 2Role of NFKB as regulator of inflammatory response
Figure 3The NFKB signaling pathway
Figure 4The Interrelationship between components of the innate and acquired immune response. It interleukin, PG, prostaglandin, TNF, tumour necrosis factor
Figure 5Beneficial effects of EPA/ DHA in cells membrane phospholipids